UK consumer goods giant Reckitt Benckiser LLC created its K-Y-branded premature ejaculation spray without stealing trade secrets from a small pharmaceutical company, according to a jury in a New Jersey federal court.
Absorption Pharmaceuticals LLC failed to show that the information at issue was protected as a trade secret or that Reckitt acted dishonestly during the company's acquisition negotiations, according to the jury.
Las Vegas-based Absorption had sought more than $450 million in damages. Reckitt had no
In a 2017 lawsuit, Absorption claimed that its Promescent lidocaine spray could treat premature ejaculation in the same way that Viagra treated erectile dysfunction. Absorption claimed it shared secrets with Reckitt during discussions about a possible acquisition.
Senior Reckitt workers tried samples of Promescent and indicated it actually works, according to the lawsuit. Absorption allegedly supplied thousands of bottles of Promescent to Reckitt for testing, according to the lawsuit.
Reckitt and Absorption finished their negotiations in 2015, and K-Y Duration commenced production in 2016. Reckitt also allegedly coerced Amazon and Target to lower Promescent's visibility in an attempt to drive the company out of business.
Reckitt also committed fraud, according to the lawsuit, by making misleading assertions about its intentions to buy Absorption, which persuaded it to reveal its secrets and turn down an offer to be acquired by another business.
In a court filing this month, Reckitt contended that it had not misled Absorption and that it had failed to discover any stolen trade secrets.


Asian Stock Markets Trade Narrowly as Year-End Volumes Thin, KOSPI Outperforms on Tech Rally
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
U.S. Government Agrees to Review Frozen NIH Diversity Research Grants After Legal Challenge
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement
Najib Razak Files Appeal Against Latest 1MDB Corruption Conviction and 15-Year Sentence
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Oil Prices Slide in 2025 as Oversupply and Geopolitical Risks Shape Market Outlook
U.S. Appeals Court Allows Trump Administration to Enforce Medicaid Funding Ban on Planned Parenthood
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 



